Lv7
4070 积分 2022-03-07 加入
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
18天前
已完结
药物诱导磷脂沉积症的安全性问题和风险控制策略
22天前
已完结
Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer
24天前
已完结
抗肿瘤分子靶向药物相关性甲沟炎的证机治要
25天前
已完结
Abstract PR010: Preliminary safety and pharmacokinetic profiles of RMC-6236, a first-in-class, RAS-selective, tri-complex RASMULTI(ON) inhibitor in patients with KRAS mutant solid tumors on the Phase 1 trial RMC-6236-001
26天前
已关闭
Targeting RAS–ERK signalling in cancer: promises and challenges
27天前
已完结
Abstract CT019: Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors
27天前
已完结
Response and Resistance to RAS Inhibition in Cancer
30天前
已完结
皖公网安备34019202002308
